The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior
20. Mai 2026 aktualisiert von: Richard Mattes, Purdue University
The Effects of GLP-1 Receptor Agonists on Sensory Systems and Ingestive Behavior
The goal of this study is to explore whether of GLP-1 receptor agonist use is associated with differences in taste, smell, food preferences, appetite, food cravings, and responses to food cues in adults. The study includes adults who are not currently taking a GLP-1 receptor agonist but may be eligible to use one, and adults who are already taking a GLP-1 receptor agonist as part of their regular medical care for approximately 1 month or approximately 6 months.
The main questions it aims to answer are:
Are taste and smell function different among adults who are not taking a GLP-1 receptor agonist and adults who have been taking one for different lengths of time? Are food preferences, appetite, food cravings, food reward, attention to food cues, and salivary responses to food cues different among these groups? Researchers will compare adults not currently taking a GLP-1 receptor agonist with adults taking a GLP-1 receptor agonist for approximately 1 month or approximately 6 months. The research team will not prescribe, assign, or provide GLP-1 receptor agonist medications.
People in the study will attend two in-person study visits, complete taste and smell tests, complete food preference and computer-based tasks, and provide saliva samples during a food cue task. Questionnaires about appetite, cravings, food cues, and eating behavior will be completed at home over approximately 2 weeks.
Studienübersicht
Status
Abgeschlossen
Detaillierte Beschreibung
This cross-sectional study examines associations between GLP-1 receptor agonist use, chemosensory function, and ingestive behavior in adults. People enrolled in the study are classified into groups based on GLP-1 receptor agonist use status and duration of use: adults who are not currently taking a GLP-1 receptor agonist but may be eligible to use one, adults taking a GLP-1 receptor agonist for approximately 1 month, and adults taking a GLP-1 receptor agonist for approximately 6 months.
GLP-1 receptor agonist use is not assigned by the research team. People who are taking these medications are using them as part of their regular medical care. The study team does not prescribe, administer, or change GLP-1 receptor agonist treatment.
Study procedures include assessments of taste and smell function, food preferences, food reward, appetite, food cravings, food cue responsivity, attentional responses to food cues, and salivary responses to a food cue. Outcomes will be compared across groups to explore whether GLP-1 receptor agonist use and duration of use are associated with differences in chemosensory function and ingestive behavior.
Studientyp
Beobachtungs
Einschreibung (Tatsächlich)
90
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Indiana
-
West Lafayette, Indiana, Vereinigte Staaten, 47906
- Purdue University
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Ja
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
Adults aged 18 to 65 years with a Body Mass Index (BMI) greater than 30 kg/m² will be recruited.
The study population includes individuals who are eligible to take GLP-1 receptor agonists but have not yet started treatment, and individuals who have been taking GLP-1 receptor agonists for weight management for approximately 1 month or approximately 6 months as part of their regular medical care.
Participants will be recruited from the general population and through healthcare providers at IU Health.
Beschreibung
Inclusion Criteria:
- Ages 18 to 65 years.
- Any sex or gender.
- Body Mass Index (BMI) >30 kg/m².
- Stable medication use, excluding weight management medications other than GLP-1 receptor agonist use as part of regular medical care.
- Eligible to take GLP-1 receptor agonists but not yet started treatment, or currently taking GLP-1 receptor agonists for weight management for approximately 1 month (±0.5 months) or approximately 6 months (±0.5 months).
- No known sensitivity or allergy to study solutions or foods, including sweet solutions, salty solutions, sour solutions, bitter solutions, fatty stimuli, common food flavors used in testing, milk, and fruit-flavored beverages.
Exclusion Criteria:
- Younger than 18 years or older than 65 years.
- Previous bariatric surgery or planned bariatric surgery within the next year.
- Sensitivity or allergy to study foods, taste solutions, odor stimuli, or food-related test materials.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Pre-use / Not Currently Taking GLP-1RA
Adults who are not currently taking a GLP-1 receptor agonist but may be eligible to use one based on body weight criteria (BMI > 30).
Participants in this group are not assigned to GLP-1 receptor agonist treatment by the study team.
|
|
Approximately 1 Month GLP-1RA Use
Adults who have been taking a GLP-1 receptor agonist as part of their regular medical care for approximately 1 month.
GLP-1 receptor agonist use is not assigned, prescribed, or modified by the study team.
|
|
Approximately 6 Months GLP-1RA Use
Adults who have been taking a GLP-1 receptor agonist as part of their regular medical care for approximately 6 months.
GLP-1 receptor agonist use is not assigned, prescribed, or modified by the study team.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Taste Detection Thresholds
Zeitfenster: During study participation, up to 2 weeks
|
Taste detection thresholds will be assessed for sweet, salty, sour, and bitter stimuli (sucrose, sodium chloride, citric acid, and urea, respectively) using a two-alternative forced-choice staircase procedure, in which participants identify which of two samples contains the taste stimulus.
Separate outcomes will be reported for each taste quality: sweet, salty, sour, and bitter.
For each taste quality, the threshold will be calculated as the geometric mean concentration at which the stimulus is reliably detected and will be reported in mmol/L.
Lower threshold values indicate greater taste sensitivity.
|
During study participation, up to 2 weeks
|
|
Suprathreshold Taste Intensity
Zeitfenster: During study participation, up to 2 weeks
|
Suprathreshold taste intensity will be assessed for sweet, salty, sour, and bitter stimuli (sucrose, sodium chloride, citric acid, and urea, respectively) using the general Labeled Magnitude Scale.
Separate outcomes will be reported for each taste quality and stimulus concentration.
For each taste quality, participants will rate the perceived intensity of suprathreshold stimulus concentrations.
The scale ranges from 0 to 100, with 0 anchored by "no sensation" and 100 anchored by "strongest imaginable sensation of any kind."
Higher scores indicate greater perceived taste intensity.
|
During study participation, up to 2 weeks
|
|
Taste Hedonics
Zeitfenster: During study participation, up to 2 weeks
|
Taste hedonics will be assessed using a food modification task in which participants create preferred concentrations for sweet, salty, sour, bitter, and fatty stimuli.
Separate outcomes will be reported for each stimulus type: sweet, salty, sour, bitter, and fatty.
For each stimulus type, the outcome will be the preferred concentration selected by the participant.
Higher values indicate preference for a higher concentration of that stimulus and do not necessarily indicate a better or worse outcome.
|
During study participation, up to 2 weeks
|
|
Fat Taste Intensity Rating
Zeitfenster: During study participation, up to 2 weeks
|
Fat taste perception will be assessed using edible strips containing different concentrations of linoleic acid.
Participants will rate the perceived intensity of each strip using the general Labeled Magnitude Scale.
Separate outcomes will be reported for each linoleic acid concentration.
The scale ranges from 0 to 100, with 0 anchored by "no sensation" and 100 anchored by "strongest imaginable sensation of any kind."
Higher scores indicate greater perceived fat taste intensity.
|
During study participation, up to 2 weeks
|
|
ArOMa-T Olfactory Test Performance
Zeitfenster: During study participation, up to 2 weeks
|
Olfactory function will be assessed using the ArOMa-T test.
Participants will smell odor stimuli and provide computer-based responses to questions assessing olfactory performance.
The outcome will be the ArOMa-T test score, with higher scores indicating better olfactory performance.
|
During study participation, up to 2 weeks
|
|
SCENTinel Olfactory Test Performance
Zeitfenster: During study participation, up to 2 weeks
|
Olfactory function will be assessed using the SCENTinel test.
Participants will smell odor stimuli and provide computer-based responses to questions assessing odor detection, odor identification, odor intensity, and odor pleasantness.
Separate outcomes will be reported for each SCENTinel component.
Higher scores indicate better odor detection or identification performance, greater perceived odor intensity, or greater perceived odor pleasantness, depending on the component assessed.
|
During study participation, up to 2 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Food Preferences
Zeitfenster: During study participation, up to 2 weeks
|
Food preferences will be assessed using the Leeds Food Preference Questionnaire.
Participants will view food images and rate how much they like and want to eat each food item.
Ratings will be used to assess explicit liking and wanting for foods.
|
During study participation, up to 2 weeks
|
|
Attentional Bias to Food Cues
Zeitfenster: During study participation, up to 2 weeks
|
Attentional bias to food cues will be assessed using a Food Stroop Task.
Participants will view food-related and non-food words and respond to the color of each word while ignoring the meaning of the word.
Response patterns will be used to assess attentional bias toward food-related cues.
|
During study participation, up to 2 weeks
|
|
Questionnaire-Based Measures of Food Cravings, Food Cue Responsivity, Food Noise, and Eating Behavior
Zeitfenster: During study participation, up to 2 weeks
|
Questionnaire-based measures will be used to assess food cravings, food cue responsivity, food-related intrusive thoughts, perceived food reward, and eating behavior.
Participants will complete the Food Cue Responsivity Scale, the Modified Trait and State Food Cravings Questionnaires, the Power of Food Scale, the Food Noise Questionnaire, and the Reasons Individuals Stop Eating Questionnaire.
These questionnaires will assess sensitivity to food-related cues, typical and momentary food cravings, food-related intrusive thoughts, perceived responsiveness to the food environment, and reasons for stopping eating, including motivations and physical cues related to meal termination and satisfaction.
|
During study participation, up to 2 weeks
|
|
Dietary Intake
Zeitfenster: During study participation, up to 2 weeks
|
Dietary intake will be assessed using ASA24, the Automated Self-Administered 24-Hour Dietary Assessment Tool.
Participants will complete three 24-hour dietary recalls on different days, including two weekdays and one weekend day, to report foods and beverages consumed over the previous 24 hours.
|
During study participation, up to 2 weeks
|
|
Cephalic-Phase Salivary Response
Zeitfenster: During study participation, up to 2 weeks
|
Cephalic-phase salivary response will be assessed by measuring saliva production at baseline and during exposure to a food cue.
Saliva will be collected during a baseline period and again while participants simulate eating a food item by focusing on its smell, taste, and texture.
Saliva will be collected in graduated tubes and weighed to quantify salivary output.
Change in salivation from baseline to food cue exposure will be compared across groups.
|
During study participation, up to 2 weeks
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Richard D Mattes, PhD, RD, MPH, Purdue University
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
20. Februar 2025
Primärer Abschluss (Tatsächlich)
4. Mai 2026
Studienabschluss (Tatsächlich)
4. Mai 2026
Studienanmeldedaten
Zuerst eingereicht
14. Mai 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
20. Mai 2026
Zuerst gepostet (Tatsächlich)
28. Mai 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
28. Mai 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
20. Mai 2026
Zuletzt verifiziert
1. Mai 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Ernährungsstörungen
- Überernährung
- Körpergewicht
- Empfindungsstörungen
- Geruchsstörungen
- Pathologische Zustände, Anzeichen und Symptome
- Verhalten
- Ernährungs- und Stoffwechselerkrankungen
- Anzeichen und Symptome
- Verhalten, Tier
- Anosmie
- Übergewicht
- Fettleibigkeit
- Fütterungsverhalten
- Essenspräferenzen
Andere Studien-ID-Nummern
- IRB-2024 - 1407
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Beschreibung des IPD-Plans
Individual participant data will not be shared because the current IRB-approved protocol does not include a formal plan for external individual participant data sharing.
Study data will be maintained in de-identified form, and identifiers/code keys will be stored separately and destroyed according to the approved protocol.
De-identified data may be used by the study team for approved secondary analyses, but individual participant data will not be made publicly available or shared externally.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .